| Identification | Back Directory | [Name]
Ezutromid | [CAS]
945531-77-1 | [Synonyms]
BMN-195
CS-2334
Ezutromid
SMT C1100
VOX C1100
VOX-C1100
Benzoxazole, 5-(ethylsulfonyl)-2-(2-naphthalenyl)-
5-(Ethylsulfonyl)-2-(naphthalen-2-yl)benzo[D] oxazole
SMT C1100; VOX C1100; BMN 195; SMT-C1100; VOX-C1100; BMN-195; BMN195 | [Molecular Formula]
C19H15NO3S | [MDL Number]
MFCD30343856 | [MOL File]
945531-77-1.mol | [Molecular Weight]
337.39 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:6.5(Max Conc. mg/mL);19.27(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.3(Max Conc. mg/mL);0.89(Max Conc. mM)
DMF:2.0(Max Conc. mg/mL);5.93(Max Conc. mM) | [form ]
A crystalline solid | [color ]
Light yellow to yellow | [InChI]
InChI=1S/C19H15NO3S/c1-2-24(21,22)16-9-10-18-17(12-16)20-19(23-18)15-8-7-13-5-3-4-6-14(13)11-15/h3-12H,2H2,1H3 | [InChIKey]
KSGCNXAZROJSNW-UHFFFAOYSA-N | [SMILES]
O1C2=CC=C(S(CC)(=O)=O)C=C2N=C1C1=CC=C2C(=C1)C=CC=C2 |
| Hazard Information | Back Directory | [in vivo]
Note: You can dissolve the products in phosphate buffered saline (PBS), 0.1% Tween-20, 5% DMSO) | [IC 50]
CYP1 | [References]
[1] Chancellor DR, et al. Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy. J Med Chem. 2011;54(9):3241-3250. DOI:10.1021/jm200135z
[2] Chatzopoulou M, et al. Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-trans-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid. J Med Chem. 2020;63(5):2547-2556. DOI:10.1021/acs.jmedchem.9b01547
[3] Tinsley JM et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One. 2011 May 6;6(5):e19189. DOI:10.1371/journal.pone.0019189
[4] Tinsley J et al. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J Clin Pharmacol. 2015 Jun;55(6):698-707. DOI:10.1002/jcph.468
[5] Guiraud S et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet. 2015 Aug 1;24(15):4212-24. DOI:10.1093/hmg/ddv154 |
|
|